HHS awards contract to make COVID-19 drug ingredients, generics in U.S.

HHS awards contract to make COVID-19 drug ingredients, generics in U.S. tjordan_drupal May 19, 2020

The Department of Health and Human Services today announced a $354 million agreement with a private partnership to make more active pharmaceutical ingredients and generic drugs in the United States to treat patients hospitalized with COVID-19 and prevent shortages of essential medicines.

Under the four-year agreement, Phlow Corporation will partner with Civica Rx, the nonprofit generic drug company created by hospital systems and others; AMPAC Fine Chemicals; the Medicines for All Institute at Virginia Commonwealth University’s College of Engineering and others